for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Almirall SA

ALM.MC

Latest Trade

14.33EUR

Change

0.14(+0.99%)

Volume

540,162

Today's Range

14.26

 - 

14.58

52 Week Range

8.84

 - 

15.35

As of on the Mercado Continuo Espana ∙ Minimum 15 minute delay

Pricing

Previous Close
14.19
Open
14.40
Volume
540,162
3M AVG Volume
7.10
Today's High
14.58
Today's Low
14.26
52 Week High
15.35
52 Week Low
8.84
Shares Out (MIL)
179.78
Market Cap (MIL)
2,551.03
Forward P/E
31.19
Dividend (Yield %)
1.32

Next Event

Q3 2021 Almirall SA Earnings Release

Latest Developments

More

Almirall Announces Issuance Of 250 Mln Euros Senior Notes Due 2026

Almirall Says Primary And All Key Secondary Endpoints Met In Phase 3 Trials Of Lebrikizumab To Treat Atopic Dermatitis

Almirall H1 Net Result Turns To Loss Of 42.8 Mln Euros YoY

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Almirall SA

Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.

Industry

Major Drugs

Contact Info

Ronda General Mitre, 151

BARCELONA, BAR

08022

Spain

+34.932.913000

https://www.almirall.es/

Executive Leadership

Jorge Gallardo Ballart

Chairman of the Board and Proprietary Director

Gianfranco Nazzi

Chief Executive Officer, Executive Director

Carlos Gallardo Pique

Second Vice Chairman of the Board and Proprietary Director

Thomas Fulton Wilson McKillop

First Vice Chairman of the Board and External Director

Michael James McClellan

Chief Financial Officer

Key Stats

1.83 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2018

0.8K

2019

0.9K

2020

0.8K

2021(E)

0.8K
EPS (EUR)

2018

0.489

2019

0.757

2020

0.525

2021(E)

0.455
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.16
Price To Book (MRQ)
2.02
Price To Cash Flow (TTM)
212.23
Total Debt To Equity (MRQ)
39.46
LT Debt To Equity (MRQ)
18.57
Return on Investment (TTM)
-0.57
Return on Equity (TTM)
-0.48

Latest News

Latest News

UPDATE 2-Spain's Almirall posts unexpected first-half loss, shares tank

Spanish drugmaker Almirall reported an unexpected first-half loss on Monday after it had written down the value of its anti-acne drug Seysara, sending its shares down as much as 9% despite an improved earnings outlook.

UPDATE 1-Almirall's 2020 net profit falls 30%, pandemic impact to continue

Spanish pharmaceutical company Almirall's said on Monday its 2020 net profit fell 29.9% to 74.3 million euros ($90.05 million) due to the impact of the coronavirus and the introduction of generic competition to one of its products.

Almirall's 2020 net profit falls 30% due to coronavirus, generics

Spanish pharmaceutical firm Almirall's 2020 net profit fell 29.9%, to 74.3 million euros ($90.05 million), due to the impact of the coronavirus and the introduction of generic competition to one of its products, the company said on Monday.

UPDATE 1-Spain's Almirall said coronavirus to hit 2020 sales, earnings

Spanish pharmaceutical firm Almirall lowered its 2020 outlook on Monday, forecasting a decrease in net sales and core earnings after the coronavirus pandemic hit its dermatology business, bringing net profit down 31.5% in the first semester.

BRIEF-Almirall Divests Ansiolin To Neuraxpharm In Italy

* SAID ON THURSDAY IT DIVESTED ANSIOLIN (DIAZEPAM) TO NEURAXPHARM IN ITALY

BRIEF-Almirall Announces FDA Approval Of Updated Label For Seysara Tablets

* ALMIRALL ANNOUNCES FDA APPROVAL OF UPDATED LABEL FOR SEYSARA® (SARECYCLINE) TABLETS

Spain's Almirall sees easing profits as virus impact evolves

Spain's Almirall's profits may shrink in the second quarter because of the coronavirus pandemic, especially in the United States, but should remain positive after a 63% rise for the first three months, the company's finance chief said on Monday.

Almirall's profit may fall in second quarter, outlook will depend on pandemic: CFO

Spain's Almirall <ALM.MC> does not expect to swing to a loss in the second quarter but its profit may decrease as it deals with the coronavirus pandemic's impact, its Chief Financial Officer Mike McClellan told Reuters on Monday .

Spain's Almirall posts Q1 net profit hike, ties outlook to coronavirus impact

Spain's Almirall reported on Monday its first quarter net profit rose 63% and kept its 2020 outlook though it added the novel coronavirus pandemic evolution in the second quarter may prompt an outlook revision.

BRIEF-Almirall Q1 Net Profit Up At 48.6 Mln Euros YoY, Maintains Guidance

* Q1 REVENUE 247.3 MILLION EUROS VERSUS 232.2 MILLION EUROS YEAR AGO

BRIEF-Almirall Cancels Ordinary Shareholders Meeting Scheduled For May 6 And May 7

* SAYS BOARD DECIDES TO CANCEL ORDINARY SHAREHOLDERS MEETING SCHEDULED FOR MAY 6 AND MAY 7 Source text: https://bit.ly/3amV95a Further company coverage: (Gdansk Newsroom)

BRIEF-Almirall Says FDA Accepts The Filing Of The New Drug Application For Tirbanibulin

* ANNOUNCES FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTANCE FOR FILING OF U.S. NEW DRUG APPLICATION (NDA) FOR TIRBANIBULIN IN ACTINIC KERATOSIS

BRIEF-Almirall: EMA Accepts Filing Of Marketing Authorization Application For Drug To Treat Actinic Keratosis

* SAYS EMA ACCEPTANCE FOR FILING OF MARKETING AUTHORIZATION APPLICATION (MAA) FOR TIRBANIBULIN IN ACTINIC KERATOSIS

UPDATE 2-Almirall lowers earnings forecast, fearing Spanish drug price moves

Almirall cut its earnings outlook on Monday, sending shares in the Spanish drugs group to their lowest level in more than 18 months, citing the impact of potential government measures in Spain and new competition in the United States.

Spain's Almirall posts 36% hike in 2019 profit

Spain's Almirall reported on Monday a 36% increase in net profit for 2019 thanks to a hike in revenue and sales.

BRIEF-Almirall And Paratek Enter Into License Agreement For Seysara In China

* SAYS ALMIRALL AND PARATEK ENTER INTO A LICENSE AGREEMENT FOR SEYSARA IN CHINA

BRIEF-Almirall FY EBITDA Up At 304.2 Mln Euros YoY

* FY NET PROFIT 105.9 MILLION EUROS VERSUS 77.7 MILLION EUROS YEAR AGO

BRIEF-Dermira Says Initiation Of First Phase 3 Clinical Study In Lebrikizumab Phase 3 Development Program Triggers A $7.5 Mln Milestone Payment By Almirall

* DERMIRA - INITIATION OF FIRST PHASE 3 CLINICAL STUDY IN LEBRIKIZUMAB PHASE 3 DEVELOPMENT PROGRAM TRIGGERS A $7.5 MILLION MILESTONE PAYMENT BY ALMIRALL

Drugmaker Almirall settles kickback allegations for $6.6 million

Spanish drugmaker Almirall has agreed to pay $6.6 million to resolve claims that its U.S. unit paid kickbacks to incentivize doctors to prescribe its dermatology products, the U.S. Justice Department and lawyers for a whistleblower said on Wednesday.

BRIEF-Almirall To Pay Scrip Dividend Of 0.198 Euros Gross/Right

* SAID ON WEDNESDAY IT WOULD INCREASE SHARE CAPITAL BY ISSUING 2.3 MILLION SHARES FOR ITS SCRIP DIVIDEND PROGRAM

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up